@article{c7a1cd2963a742e0b0601136292f758f,
title = "Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2 seropositive persons during early HIV-1 infection",
abstract = "We evaluated whether acyclovir suppression during human immunodeficiency virus type 1 (HIV-1) acquisition reduces HIV-1 set point, increases CD4 cell counts, and selects reverse- transcriptase mutations among 76 HIV-1 seroconverters identified in a placebo-controlled trial of twice-daily acyclovir (400 mg) for the prevention of HIV acquisition in herpes simplex virus type 2 (HSV-2)-seropositive persons(HIV Prevention Trials Network study 039). We found no significant difference in plasma HIV-1 RNA levels (Pp.30) or CD4 cell counts (Pp.85) between the acyclovir and placebo recipients. V75I and other mutations in HIV-1 reverse transcriptase reported from in vitro acyclovir studies were not observed. In conclusion, acyclovir suppression during HIV-1 seroconversion and the subsequent 6 months does not affect HIV-1 set point.",
author = "{Nina Kim}, H. and Jing Wang and James Hughes and Robert Coombs and Jorge Sanchez and Stewart Reid and Sinead Delany-Moretlwe and Frances Cowan and Jonathan Fuchs and Eshleman, {Susan H.} and Leila Khaki and McMahon, {Moira A.} and Siliciano, {Robert F.} and Anna Wald and Connie Celum",
note = "Funding Information: Potential conflicts of interest: C.C. has received research grant support (which did not include salary support) from GlaxoSmithKline. A.W. has received grant support from Glaxo-SmithKline and Antigenics; she has been a consultant for Novartis, PowderMed, and Medi-Gene and a speaker for Merck Vaccines. R.C. serves on an advisory board for Merck. All other authors report no potential conflicts. Funding Information: Financial support: This study was supported by the HIV Prevention Trials Network and was sponsored by the National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research of the US National Institutes of Health, US Department of Health and Human Services, under cooperative agreement U01 AI46749 as well as a cooperative agreement with the University of Washington (U01 AI52054), with subcontracts to the Asociacion Civil Impacta Salud y Educacion (IMPACTA); HIV Research Section, San Francisco Department of Public Health; the New York Blood Center; the University of Alabama at Birmingham; the University of California, San Francisco; and the University of the Witswatersrand. Study drug was purchased with a grant provided by GlaxoSmithKline.",
year = "2010",
month = sep,
day = "1",
doi = "10.1086/655662",
language = "English (US)",
volume = "202",
pages = "734--738",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",
}